3 Popular Biotech Stocks to Buy on Sector Buzz
Over the past years, the biotech sector has grown at a breakneck pace, so it’s only natural that biotech stocks have emerged as one of the more popular sectors among investors during this period. The ... [Read]
AMRN Stock Tanks: Earnings and Revenue Top Analyst Estimates
AMRN stock is trading weakly despite Amarin Corp (NASDAQ:AMRN) releasing its Q4 and full-year results, which topped both revenue and earnings estimates set by Wall Street analysts. The impressive results were mainly due to successful ... [Read]
KOD Stock Soars After Early-Stage Data for KSI-301
In a development that would come as a major boost to KOD stock, Kodiak Sciences Inc (NASDAQ:KOD) announced impressive results from the clinical trial of one of its products. The company presented the data from ... [Read]
JNJ Stock Sinks Following $344 Million Marketing Lawsuit
JNJ stock is in the red today after a California judge ordered Johnson & Johnson (NYSE:JNJ) to pay nearly US$344 million for deceptively marketing pelvic mesh devices for women. San Diego Superior Court Judge Eddie ... [Read]
XLRN Stock Hits New High on Positive Trial Results of PAH Treatment
XLRN stock surged 43% on Tuesday after Acceleron Pharma Inc. (NASDAQ:XLRN) announced that its trial treatment for pulmonary arterial hypertension (PAH), sotatercept, had met its primary endpoint midway in the study. Acceleron Lifted By Trial ... [Read]
JNJ Stock Gains Slightly on $2 Million USD Talc Case Settlement
JNJ stock is making minor gains on Tuesday after it was reported that pharmaceutical heavyweight Johnson & Johnson Inc (NYSE:JNJ) settled a lawsuit against it, which claimed that its talcum powder contained asbestos. Johnson & ... [Read]
APLS Stock Hits All-Time High: APL-2’s Phase 3 Impressive Results
Positive results from late-stage clinical trials almost always prove to be a major positive for the stock of any pharmaceutical company, and that is what happened with APLS stock this morning. In a new development, ... [Read]
BLUE Stock Gains 20% in Two Weeks: Key Factors to Watch
Biotech stocks are usually tricky to invest in, and they are not for faint-hearted investors. They are a high-risk investment because the companies have no guarantee their drugs will be successful. A mistake in the ... [Read]
AMRN Stock Jumps 5% After FDA Approves Vascepa for Wider Use
AMRN stock jumped to a new decade high on Monday following FDA marketing approval for Amarin Corporation’s (NASDAQ:AMRN) drug Vascepa. Expanded Approval of Vascepa The regulator approved the drug for expanded use in preventing cardiovascular ... [Read]
SRPT Stock Surges 36% After FDA Approves Duchenne Drug
SRPT stock jumped 32% in early trading on Friday after the FDA approved the genetic medicine developed by Sarepta Therapeutics (NASDAQ:SRPT), the muscular dystrophy drug Vyondys 53. FDA Approves Vyondys 53 for Treatment of Duchenne ... [Read]